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AT Expandability Hypothesis
(1β,1γ) In the course of obesity, almost the entire spectrum of immune cells becomes apparent within the AT.(1β)
Macrophages are abundantly present in AT.
Resident macrophages in lean AT have an antiinlammatory Mβ-like phenotype characterized by the surface expression of cluster of differentiation (CD)β06 and macrophage galactose-type C lectin 1 (MGL-1), produces anti-inlammatory mediators such as IL-10, and play a critical role in the maintenance of AT insulin sensitivity. (14) During obesity, the majority of macrophages recruited have a proinlammatory M1 proile characterized by the expression of CD11c, inducible nitric oxide synthase (iNOS), TNF-α, and IL-6 and reside in crown-like structures that surround necrotic adipocytes. (14) Besides the classical M1 and M2 macrophages, the obese AT contains a mixed macrophage population, that expresses both CD11c and CDβ06 which also has a proinlammatory phenotype that promotes AT ibrosis and IR. (15) Neutrophils are recruited to the AT within one week after the start of a high-fat diet (HFD), albeit in low numbers. Genetic deiciency and pharmacologic inhibition of neutrophil elastase improve glucose tolerance and insulin sensitivity by the reduced neutrophil elastasemediated degradation of insulin receptor substrate (IRS) indirectly activated through lipid-induced TLR signaling or through T-cell-dependent mechanisms, respectively, to produce immunoglobulin Gβc (auto) antibodies that promote AT inlammation and IR. (11) A major obstacle to effective obesity treatment is that lost weight tends to be regained over time.(βγ) Although the mechanisms underlying recovery of lost weight are incompletely understood, a large literature proposes that body fat stores are subject to homeostatic regulation, and that the process occurs in obese as well as normalweight individuals. Caloric restriction for a period of time showed gradually weight lost in most individuals, but then inexorably recovered. This effect involves the capacity of the brain to sense the reduction of body energy stores and activate responses to compensate for this deicit. In simple terms, voluntary weight loss triggers increases appetite and energy eficiency, such that both sides of the energy balance equation shift in favor of weight gain.(β4,β5)
From this perspective, obesity can be viewed as a disorder in which the biologically defended level of body fat mass is increased. Recent indings implicate inlammation in hypothalamic areas for body weight control in this process. These evidences suggests that obesity activates a complex immunological mechanisms involving a delicate interaction between both innate and adaptive immune systems. (11) Anatomically, AT can be divided into truncal or peripheral region. Truncal AT includes subcutaneous fat in thoracic and abdominal region and also intrathoracic and intraabdominal fat depots.(β6) Peripheral AT includes subcutaneous depots in upper and lower extremities. Whether accumulation of AT in a particular region contributes to increased risk of IR development and metabolic consequences or not is still controversial.(β7) There are also important adipose depots within the abdominal cavity, called visceral AT (VAT), and around other organs, for example, perirenal, epi-and pericardial fats. Perfusion of VAT regulation is potentially very interesting in view of the relationships between VAT and adverse metabolic proile.(β8)
VAT has increased metabolic activity, both lipogenesis and lipolysis, compared to other fat depots. Free fatty acid (FFA), product of lipolysis, can directly enter liver via portal circulation and lead to increased lipid synthesis, gluconeogenesis and IR, resulting in hyperlipidemia, glucose intolerance, hypertension, and ultimately atherosclerosis. depots, it should be the main source of systemic FFA lux.
Only small portion of total body fat, 15-18% in men and 7-8% in women, is located in abdominal cavity.(γ0) VAT contributes to only 15% of the total systemic FFAs whereas the majority of FFAs are contributed by nonsplanchnic AT.(β6,γ1) This raises doubt over contribution of VAT to peripheral insulin sensitivity. However, we have to remember that elevated waist circumference does not always indicate increased visceral adiposity but instead can also indicate increased subcutaneous adiposity. Subcutaneous AT (SAT) represents about 85% of all body fat. Its primary metabolic role is to regulate storage and mobilization of lipid energy. It stores lipid in the form of triacylglycerol (TG), which can be mobilized, as required by other tissues, in the form of nonesteriied fatty acids (NEFA). Neither TG nor NEFA are soluble to any extent in water, and their transport to and out of the tissue requires special transport mechanisms and adequate blood low. SAT blood low is therefore tightly linked to the tissue's metabolic function.(β8)
Obesity is associated with impaired lipid storage capacity in SAT. Lipid "spillover" which is occurs as a result leads to lipid deposition in VAT and, subsequently, the liver.(9,γβ) The excess fat triggers inlammatory pathways in VAT, and the propagation of inlammation signals from adipose into other metabolic tissues induces systemic IR, liver steatosis, and further progression of obesity, creating a vicious cycle.(9,γγ) We concluded that subcutaneous truncal fat plays a major role in obesity-related IR in comparison to intraperitoneal (visceral) or retroperitoneal fat.
Simple explanation for stronger relationship between SAT and insulin sensitivity comes from larger volume of SAT mass. The subcutaneous abdominal fat mass is approximately twice more than intraperitoneal fat mass and total subcutaneous truncal fat mass can be 4-5 times larger than intraperitoneal fat mass.(γ4-γ6) Unger and Scherer proposed that lipotoxicity promote IR, hyperlipidemia, elevated abdominal fat, and hypertension, known as metabolic syndrome outriding the onset of type 2 diabetes mellitus onset in obese.(γ7-γ9)
The underlying mechanism linking lipotoxic obesity with IR is widely believed to be impaired adipogenesis, which is manifested as the presence of enlarged subcutaneous adipocytes.(40) Larger adipocytes are thought to be close to a hypothesized critical volume where further expansion is no longer possible; therefore, excess lipid is shunted instead to nonATs (skeletal muscle, liver, heart, and pancreas), where it interferes with insulin signaling and causes tissue IR. (41) Enlarged adipocytes may also secrete chemoattractants or have localized hypoxia, which trigger macrophage iniltration and activate the inlammatory process in AT, thus worsening IR.(4β,4γ) AT containing primarily large adipocytes is more insulin resistant, as illustrated by reduced suppression of FFA production, resulting in elevated FFAs, which can directly activate inlammation via TLR.(44)
With the assumption of equal metabolic activity in subcutaneous truncal and intraperitoneal fat, subcutaneous truncal fat should release more FFAs in systemic circulation and should have much larger impact on peripheral insulin sensitivity. As we mentioned earlier, major contributor of FFAs in systemic circulation is nonsplanchnic AT.(β7) In comparison to noninlamed subcutaneous abdominal adipose phenotype, inlamed phenotype, characterized by presence of macrophage in crown-like structures, was associated with systemic hyperinsulinemia, IR, impaired endothelium-dependent low-mediated vasodilatation, and elevated plasma high-sensitivity C-reactive protein (hsCRP) levels. Other investigators have also reported similar association between macrophage iniltration in SAT and IR, and low grade systemic inlammation.(4γ,45)
Obese people who are "metabolically healthy" have greater adipogenesis (smaller subcutaneous fat cells) along with less visceral adiposity and hepatic lipid accumulation, decreased inlammation, and preserved insulin sensitivity compared with metabolically unhealthy obese.(46-48) It shows that individuals with larger fat cells would have less capacity to expand their SAT and would deposit more lipid into ectopic depots, thus worsening the metabolic response.
AT as An Immunologic Organ
Current approaches for the treatment of obesity, including diet and lifestyle changes, have not been pretty fruitful in curtailing the obesity epidemic.(49) Emerging evidence has stated that obesity is characterized by chronic and low-grade inlammation accompanied by macrophage accumulation in the AT, which eventually leads to metabolic diseases, including IR and type β diabetes mellitus .(50-5β)
Increased ATM play crucial roles in the altered production of proinlammatory cytokines in the AT of obesity.(5γ) Improved understanding of the immunological processes that regulate obesity may yield new treatments for obesityassociated disorders.
Plenty of immune cells including B-cells, T-cells, macrophages, and neutrophils have been identiied in AT. Obesity inluences both the quantity and the nature of immune cell subtypes, that emerges as an active immunological organ capable of modifying whole-body metabolism through paracrine and endocrine mechanisms. AT is a large immunologically active organ during obesity and displays hallmarks of both innate and adaptive immune response.(54) During obesity, AT mass increases by hyperplasia and hypertrophy, the latter being associated with activation of stress signaling pathways in adipocytes resulting cell death. For instance, hypertrophic adipocytes are under constant stress, as evidenced by increase in endoplasmic reticulum (ER) stress, hypoxic responses, release of FFAs and increased production of reactive oxygen species (ROS). Considering that in severe obesity in humans, the total fat content can constitute up to 50% of total body mass, AT thus represents an uncharacterized immunological organ. For such an immunological characterization, speciic cells in AT must be able to capture, process, present antigens to T cells and mount a functional immunological response. Morris, et al., further hypothesize that AT is immunologically aware by providing new evidence that ATMs serve as predominant antigen-presenting cells (APC) that are fully competent to control the antigen-speciic T-cell response in the AT of lean as well as obese mice.(61,6β) They provide evidence that HFD feeding increases major histocompatibility complex (MHC)-II expression on ATMs and that most of this expression was localized in the "crown-like structures" and "fat-associated lymphoid clusters" in the AT, the major sites of macrophage residence in AT. Furthermore, HFD feeding increases the expression of co-stimulatory molecules on the ATM. Rather than simple inlammatory disease, obesity and metabolic syndrome represent derangements in macrophage activation with concomitant loss of metabolic coordination. As such, the sequelae of obesity are as much products of the loss of positive macrophage inluences as the presence of deleterious inlammation. The therapeutic implications of this conclusion are profound because they recommend that pharmacologic targeting of macrophage activation, rather than purely inlammation, might be eficacious in treating this global epidemic.(100) 
Adipocyte Remodeling
Obesity is characterized by the accumulation of fat mass and is often associated with AT dysfunction.(101) Expansion of AT can be achieved by hyperplasia (increase in adipocyte number) or hypertrophy (increase in adipocyte size) or the combination of both.(10β,10γ) AT can respond rapidly and dynamically to alterations in nutrient deprivation and excess through adipocyte hypertrophy and hyperplasia, thereby fulilling its major role in whole body energy homeostasis.(7γ) AT remodeling is an ongoing process that is pathologically accelerated in the obese state, and thus, features such as reduced angiogenic remodeling, extracellular matrix (ECM) overproduction, a heightened state of immune cell iniltration and subsequent proinlammatory responses prevail in many obese fatpads.(104) However, not all AT expansion is necessarily associated with pathological changes. The concept of "metabolically healthy obese (MHO)" suggests that some individuals can preserve systemic insulin sensitivity on the basis of "healthy" AT expansion (105) , bypassing all of the aforementioned pathological consequences associated with obesity (γ7), thereby also avoiding the obesity-associated lipotoxic side effects.
In β007, Saltiel and colleagues proposed a model of "phenotypic switching" that captured the very essence by which enhanced ATM iniltration exacerbates the milieu of obesity-related inlammation. (14) Their model emphasized that obesity is accompanied by a transformation in the polarized states of macrophages, from an antiinlammatory "alternatively activated" Mβ form which primarily accumulates during negative energy balance (109) , to a more proinlammatory "classically activated" M1 form (110) . The M1 population demonstrates a positive correlation with IR and dominates in states of overnutrition by targeting FFAmediated increases in proinlammatory responses. (110, 111) The polarization of resident macrophages will go toward an M2 status in lean states, presented by the expression of F4/80, CD301, IL-10, and arginase 1 expression as its hallmark (14), and iNOS activity inhibition. While not only opening up a newfound fundamental role for the macrophage in metabolism, these reports also fueled the publication of numerous additional papers, thus irmly establishing the phenomenon of a macrophage-orchestrated inlammatory response co-existing with obesity-induced IR.
Supporting this hypothesis, large clusters of macrophagerelated inlammatory genes were identiied as signiicantly altered in obese AT. (64,7γ) In order to expand health and properly, adipocytes need a well coordination between the oxygen diffusion limit and promptly many cell types responses, including endothelial precursor cells, immune cells and preadipocytes. as a heterodimer, consisting of an oxygen sensitive HIF-1α subunit and a constitutively expressed HIF-1 subunit. While HIF-1α synthesis is O 2 independent, its degradation is enhanced under normoxic conditions.(108) As such, O 2 can mediate the prolyl hydroxylation of HIF-1α, which subsequently facilitates ubiquitination by ubiquitin E3 ligase. This ligase contains a von Hippel-Lindau tumor-suppressor protein, which speciically recognizes the hydroxylated form of HIF-1α and targets it for ubiquitination and degradation.
As the result of this aberrant HIF-mediated transcriptional program, the ECM in white AT (WAT) accumulates ibrillar collagens. The upregulation of ECM then causes local ibrosis, and that hypoxia-induced ibrosis in AT may be a key factor that ultimately stimulates the local inlammatory responses. Although adipocyte is the key player orchestrating local changes in the microenvironment, much evidence also points toward pivotal role for macrophages in such remodeling events. Resident ATMs display remarkable heterogeneity in their activities and functions (65) , largely relecting the complex events occurring in AT during metabolic and immune perturbations (7γ).
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through a variety of signaling pathways. (118) Metabolism and immunity are two fundamental systems. The presence of immune cells, such as macrophages, in metabolic tissues, suggests dynamic, ongoing crosstalk between these two regulatory systems. (57) The complex events that must occur in order for an organ such as AT to rapidly remodel and either release or accept a large number of calorically dense lipids that have the potential to be potently cytotoxic. A well-orchestrated set of interactions between a number of critical cell types has to take place in a deined chronological order, with many pathological changes that can occur during that process. 
Adiposopathy and Adipocyte Dysfunction
The problems associated with obesity develop initially as a problem related to energy storage, thereby placing WAT at the front lines. In addition to energy storage, WAT also acts to buffer postprandial amount of circulating fatty acids, so excessive lipid won't be accumulated in peripheral tissue (1β1), and most prominent energy-storing cells in WAT, adipocytes, secrete hormones called adipokines that affect a diverse array of local and systemic functions. WAT consists of a SVF comprised of preadipocytes, endothelial cells, ibroblasts, macrophages, monocytes, and lymphocytes, which also holds important metabolic and immunological roles.(1ββ)
Adiposity is excessive AT. Those with adiposity are characterized as being overweight or obese. Obesity is described as an independent risk factor for cardiovascular disease (CVD).(1βγ) Adiposity is pathological to the cardiovascular system through excessive fat-mass mechanisms and through adipocyte and AT dysfunction. (1β4) Adiposopathy (or "sick fat") is deined as pathologic AT anatomic/functional disturbances promoted by positive caloric balance in genetically and environmentally susceptible individuals that result in adverse endocrine and immune responses that may directly promote CVD, and may cause or worsen metabolic disease. Because many of these metabolic diseases are major CVD risk factors (e.g., type 2 diabetes mellitus, high blood pressure, and dyslipidemia), adiposopathy also indirectly increases CVD risk. (1β5-1β8) AT is a loose ibrous connective tissue packed with many cells (called "adipocytes") surrounded by collagen, nerves, and blood vessels that are specialized for storage of triglycerides more commonly referred to as "fats".(1βγ) AT's supporting framework contains SVF cells, which include Central obesity is a clinical marker for adiposopathy. Increased waist circumference, relecting increased VAT as a surrogate marker for SAT dysfunction, and a shared pathogenic fat accumulation process and fatty iniltration of nonadipose body organs. AT has long been recognized as the body's largest pool of free cholesterol. Through multiple release and uptake pathways, the adipocyte establishes a communication between its free cholesterol depot and the blood cholesterol pool and in turn maintains cellular Hypoxic AT has unique alterations that are likely contributors toward the link of obesity with its comorbidities. Fibrosis is a hallmark of metabolically dysfunctional AT. Adipocytes are surrounded by a network of ECM proteins that serve as mechanical support and that respond to different signaling events.(117) Maintaining a high degree of lexibility of the ECM allows AT to expand in a healthy manner, without adverse metabolic consequences. Over the course of the development of obesity, increased interstitial ibrosis in WAT may decrease ECM lexibility and reduce the tissue plasticity, which ultimately leads to adipocyte dysfunction. Of note, abnormal collagen deposition, a hallmark of ibrosis development in AT, is tightly associated with tissue inlammation characterized by iniltration of macrophages and many other immune cells.(7γ) Thus, ibrosis is increasingly appreciated as a major player in AT dysfunction.(1γ4) "Sick" adipocytes termed to the disrupted physiological function of fat-cell organelles characterized by increased markers of intracellular ER stress and mitochondrial dysfunction associated with inlammation, cellular dysfunction, and metabolic disease due to excessive adipocyte hypertrophy.(1γ1,1γ5-1γ7) The endoplasmic reticulum is a membrane system of folded sacs and interconnected channels that serves as a site for protein and lipid synthesis, also transport proteins and carbohydrates so the normal cellular functions can take place. Mitochondria are membrane-enclosed organelles that contain enzymes responsible for transforming nutrients into cellular energy through the production of adenosine triphosphate. Increased markers of adipocyte mitochondrial stress are associated with obesity, IR, and type β diabetes mellitus.(1γ8)
AT dysfunction belongs to the early abnormalities in the development of obesity and seems to be an important Obesity is typically associated with increased risk of cardiovascular events. However, a subset of obese individuals does not present phenotypic traits that characterize increased cardiovascular risk, such as IR. The condition stated above has been called MHO. Indeed, 10-25% of obese individuals may not be impacted by metabolic abnormalities (157), which is a substantial number considering that obesity affects 300 million people worldwide. In a sub-analysis of the National Health and Nutrition Examination Surveys 1999β004, 51.γ% of overweight adults and γ1.7% of obese adults were metabolically healthy as they showed either no or one metabolic syndrome trait. (158) The concept of healthy obesity challenges the notion that all overweight and obese individuals should be treated. Selecting such individuals for watchful surveillance could spare signiicant amounts of societal and economic resources. (159) The phenotype of the 'metabolically obese but normal weight (MONW)' individual, irst identiied by Ruderman "Metabolically Healthy" Obesity and colleagues, and characterized by hyperinsulinemia, hyperglycemia, IR, impaired glucose tolerance, hypercholesterolemia and hypertriglyceridemia, but normal adipocyte volume and BMI, suggests that there must be genes and signal transduction pathways that ordinarily couple obesity to IR, and that these are deicient in certain individuals. (158, 160) These characteristics in a lean individual mark a departure from common human patterns, in which metabolic disease is a consequence of weight gain. Yet, these phenotypes are very prevalent. For example, polycystic ovary syndrome (PCOS) has been diagnosed in up to 10% of one study of women of reproductive age (161) and MONW in 1β.7% of normal-weight subjects in a Korean study (16β) . Elevated risk for CVD is seen among both MONW (16γ) and PCOS individuals (161) , as well as elevated risk for hypertension, type 2 diabetes mellitus and other metabolic complications. Thus, metabolic dysfunction and CVD risk come in many sizes and shapes. (164) Although adipose depots all increase in volume with obesity, fat deposits in different anatomical regions show depot-associated levels of immune cell iniltration and inlammation, and thus differentially associate with disease.
To generalize, SAT is more metabolically 'protective', meanwhile pericardial and other visceral depots are highly correlated with risk for obesity-associated disease, including coronary artery disease. (165) (166) (167) (168) The MHO phenotype is strongly associated with a smaller visceral depot, although no necessarily with expanded subcutaneous; the clamped glucose infusion rate strongly correlates with visceral WAT area.(46) Population studies propose that propensity to accumulate fat in central oFr peripheral depots has a strong genetic component (169, 170) , thus certain features of the MHO phenotype are likely to be heritable (171) , including body fat distribution. AT depots which preferentially expand in metabolically unhealthy (inlammatory) responses include pericardial (epicardial and interstitial) and visceral depots. AT that preferentially expands in MHO individuals includes widespread subcutaneous depots ( Figure 5) . (17β) In humans, WAT ibrosis as measured by collagen VI expression is positively correlated with IR and inlammatory markers, such as the number of ATM. (17γ) The relationship between stress/ibrosis and unhealthy WAT supports a hypothesis that alleles of genes that encode different forms of collagen or enzymes that modify collagen, such as lysyl oxidase (174, 175) , correlate with the ability of WAT to expand and remodel in obesity while avoiding stress and remaining metabolically healthy. Adipocyte size per se in both omental and subcutaneous depots is also strongly negatively correlated with metabolic health (46,17γ), with smaller adipocytes and preserved insulin-sensitive glucose transport characteristic of MHO individuals, while some of them based on functional allelic variants of peroxisome proliferator-activated receptor (PPAR)-, PPAR-g coactivator (PGC)-1α, positive regulatory domain-containing 16 (PRDM16) and other adipogenic transcriptional program could expanded subcutaneous WAT then increased adipogenesis.
Not much clinical evidence has yet been assembled to support this idea, even though Patti, et al., noted in a study of Mexican-American subjects that expression of PGC-1α and PPAR -directed transcriptional networks are decreased in pre-diabetic and type β diabetes obese subjects. (176) Their metabolic dysfunction, including reduced oxidative metabolism and attenuated mitochondrial electron transport, is consistent with defective PGC-1α and PPAR function, although primary adipogenesis was not studied in this cohort. Well matched MHO and IR obese human subjects should be evaluated for these hypothesized variants. (164) MHO individuals display a reduced inlammatory proile (47), with reduce hepatosteatosis (48), lower numbers of iniltrating ATMs and crown-like structures in WAT (46) and reduced serum levels of TNF-α, monocyte chemotactic protein-1 (48), IL-6 and C-reactive protein (CRP) (46). Elevated serum adiponectin and reduced ATM iniltration are the strongest predictors of preserved ability to clear glucose (46,177); in men, preserved adiponectin levels are associated with a reduced rate of myocardial infarction (178) . Adiponectin also promotes protective Mβ macrophage differentiation. (179) A more precise term might be 'metabolically protected obese'. This is because not only are a number of deleterious factors reduced in these individuals, but Metainflammation and Obesity Management Meiliana A, et al.) )ndones Biomed J. ; :
other protective factors are relatively undiminished, such as serum adiponectin. (18β,18γ) In some MHO subjects, adiponectin concentrations even exceed the values seen in normal BMI individuals.(184) Interestingly, a meta-analysis of PCOS women showed that both lean and obese subjects have signiicantly lower adiponectin than the normal controls (185), consistent with the contention that increased metabolic risk need not be a result of elevated BMI. (164) Triglycerides, HDL cholesterol, and hsCRP may be useful markers for predicting which individuals will develop MHO, and which will go on to develop metabolically unhealthy obesity. MHO may not be a stable condition, because it confers markedly increased risk of developing multiple metabolic abnormalities in the future. (186) Complication Centric Approach to Obesity Management
Obesity is arguably the most common medical problem seen today in primary care (187) , and is a disease that adversely affects mortality, morbidity, and quality of life as a result of its associated complications (188, 189) . These complications can broadly be categorized as cardiometabolic, mechanical, and lifestyle based. The health risks associated with being overweight and obese include a range of conditions, including diabetes, CVD, hypertension, dyslipidemia, sleep apnea, some cancers, musculoskeletal disease, infertility, disability, dementia, and mortality. (1, 19, 190) Moderate weight loss (5-10%) has been associated with improvements in these obesity-related comorbidities (191) , with lifestyle modiication, pharmacotherapy, and bariatric surgery representing the three available treatment options. Currently, BMI still used as a predominant measure used to gauge obesity-related disease severity and treatment modalities, but recent understanding in obesity treatment and relationship between BMI and obesity-related complications convince us that this BMI-centric medical model has to be re-examined. A major shortcoming of BMI as a measure of adiposity is that the numerator (weight) of the index fails to distinguish between lean and fat mass.(19β-194) Variables that limit BMI as a comparative measure include aging, sex, physical itness and muscular build, weight loss with exercise, racial differences, and clinical disease. (195) (196) (197) A systematic review found that around 50% of individuals not labeled as obese by BMI might indeed have excess adiposity, helping to elaborate why BMI is a poor discriminator of cardiovascular risk in people with intermediate BMI (below γ0) values. (198) The relationship between generalized obesity, as measured by the BMI, and its associated comorbidities is complex. Obesity can exacerbate IR and impel cardiometabolic disease progression to metabolic syndrome, prediabetes, diabetes, and CVD. However, IR exists largely independent of BMI, and BMI is a poor predictor of CVD when compared with other measurements such as waist/hip ratio.(199-β04) Importantly, up to γ0% of obese individuals (BMI ≥γ0) are relatively insulin sensitive and do not have manifestations of cardiometabolic disease (i.e., the MHO), and up to 30% of lean individuals are insulin resistant with cardiometabolic disease manifestations. (β0β,β05,β06 ) Thus, obesity is neither necessary nor suficient to explain the pathophysiology underlying cardiometabolic disease. Similarly, regarding the mechanical complications of obesity, the presence and severity of obstructive sleep apnea (OSA), osteoarthritis, gastroesophageal relux disease (GERD), and stress incontinence can be poorly correlated with the BMI level. (β01) Denis and Hamilton at the Boston University Medical Center who have investigated the metabolically unhealthy obese, compared to the MHO, and found that a distinguishing factor could be the accumulation of not just visceral body fat but ectopic fat in the pericardial space.(β07) Favorable inlammatory status is positively associated with metabolic health in obese and non-obese individuals. These indings are of public health and clinical signiicance in terms of screening and stratiication based on metabolic health phenotype to identify those at greatest cardiometabolic risk for whom appropriate therapeutic or intervention strategies should be developed. (β08) A complications-centric approach to obesity management identiies patients who will beneit most from weight loss, and optimizes patient outcomes, beneit/ risk ratio, and the cost-effectiveness of interventions. In a complications-centric model, the existence and severity of complications at baseline is more important than the baseline BMI itself in determining the treatment modality and intensity for obesity.(β09-β11) Therefore, in order to develop an appropriate therapeutic strategy, irst we have to evaluate the severity of patients' obesity complication.
The clinician should evaluate patients for the metabolic syndrome and prediabetes, as this effectively identiies individuals at high risk for future diabetes and CVD. (β1β,β1γ) The initial evaluation should also screen for other disease entities that will beneit from weight loss, including nonalcoholic fatty liver disease (NAFLD) and sleep apnea.
Finally, mechanical complications such as problematic degenerative joint disease, GERD, stress incontinence, and immobility/disability also have to be evaluate. (198 scoring systems that are complications-centric offer a better methodology to gauge severity and direct intervention, but these tools will need to be validated in many settings. The study by Daniel, et al., discusses such scoring systems and some have been published recently such as the Edmonton Obesity Staging System (EOSS) (β14) and the American Association of Clinical Endocrinologist (AACE) Complications-Centric Obesity algorithm (β1β).
The EOSS is a important guideline for obesity management as it integrates an evaluation of the severity of both cardiometabolic disease and mechanical complications together with an assessment of functional impairment. However, it has two limitations. First the assessments are not quantitative and staging depends largely on clinical judgment. Second, it lacks granularity for cardiometabolic disease staging (CMDS). All patients with IR, prediabetes, metabolic syndrome, elevated hepatic transaminases, borderline hypertension, moderate dyspnea on exertion, and mild impairment of well-being are included within stage 1, which encompasses a wide range of risk for (Table 1A) . (198) Garvey and coworkers have recently proposed CMDS System as a guide for treatment of obesity or other interventions intended to treat or prevent diabetes and CVD risk.(β09,β11) CMDS is a single staging system that provides a quantitative assessment of risk for both future diabetes and all-cause and CVD mortality. CMDS assigns patients to one of ive risk categories using quantitative parameters readily available to the clinician, including waist circumference, SBP and DBP, fasting blood levels of glucose, triglycerides, and HDL cholesterol, as well as the 2-h oral glucose tolerance test value. With advancement from stage 0 to stage 4, there are signiicant increments in risk and adjusted hazard ratio for diabetes as validated using the Coronary Artery Risk Development in Young Adults study national cohort, as well as increased risk and hazard ratios for both all-cause and CVD-related mortality in the National Health and Nutrition Examination Survey cohort.(β11) This staging system provides a strong predictor of diabetes, CVD mortality, and all-cause mortality independent of BMI (Table 1B) .
Conclusion
Even though BMI is the currently accepted means to deine obesity, it is a crude estimate of body fat and the correlation between body fat and risk of mortality from diabetes and heart disease is not perfect. Advancements in treatment modalities for obesity have enabled development of medical models for management. A complications-centric model that employs weight loss as a tool to treat and prevent obesity comorbidities will assure that the aggressiveness of therapy is commensurate with disease severity. This approach is designed to identify patients who will most beneit from weight loss, and optimize patient outcomes, the beneit/risk ratio, and the cost-effectiveness of interventions.
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